1-(3,4-二异丙基苯基)乙酮 | 94291-81-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3,4-二异丙基苯基)乙酮
• 英文名称: 1-(3,4-diisopropyl-phenyl)-ethanone
• 英文别名: 1-(3,4-Diisopropyl-phenyl)-aethanon；1-(3,4-bis(1-methylethyl)phenyl)ethan-1-one；1-[3,4-di(propan-2-yl)phenyl]ethanone
• CAS: 94291-81-3
• 化学式: C₁₄H₂₀O
• 分子量: 204.312
• InChiKey: ZDINBUUATIMDHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914399090

反应信息

• 作为反应物：
  描述：

  1-(3,4-二异丙基苯基)乙酮 在 potassium permanganate 作用下， 生成 3,4-diisopropyl-benzoic acid
  参考文献：
  名称：

  Wolkow; Sawgorodnii, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3672,3676; engl. Ausg. S. 3630, 3633

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2,4-三异丙基苯 在 air 、 manganese resinate 、 sodium carbonate 作用下， 生成 1-(3,4-二异丙基苯基)乙酮
  参考文献：
  名称：

  Wolkow; Sawgorodnii, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3672,3676; engl. Ausg. S. 3630, 3633

  摘要：

  DOI：

文献信息

• Asthma and allergic inflammation modulators
  申请人：Fu Zice

  公开号：US20080085891A1

  公开（公告）日：2008-04-10

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

  本发明提供了在治疗炎症和免疫相关疾病和病况方面有用的化合物、制药组合物和方法。特别是，本发明提供了调节参与过敏性疾病、炎症病况和癌症的蛋白质的功能和/或表达的化合物。所述化合物为羧酸衍生物。
• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20140155384A1

  公开（公告）日：2014-06-05

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  描述了氢化吡啶并[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体a2A。这些化合物也可以结合并拮抗肾上腺素受体α2B；或这些化合物不是肾上腺素受体α2β的拮抗剂，并且这些化合物与第二种预计可以降低血压的药物一起使用于个体中。这些化合物可以用于治疗，例如，调节血糖水平，增加胰岛素分泌和治疗疾病或病况，这些疾病或病况对胰岛素产生增加反应。特别描述了使用这些化合物治疗2型糖尿病。
• COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION
  申请人：Protter Andrew Asher

  公开号：US20140296209A1

  公开（公告）日：2014-10-02

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 1B —The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文描述了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体α2B。这些化合物还可以结合并拮抗肾上腺素受体α1B。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可以用于治疗预计对降低血压有响应的疾病或病况。本文特别描述了使用这些化合物治疗心血管和肾脏疾病的情况。
• PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130190293A1

  公开（公告）日：2013-07-25

  This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文披露了四环吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚。该化合物的药物组合物也被提供，以及使用该化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING HYPERTENSION
  申请人：Protter Andrew Asher

  公开号：US20140303144A1

  公开（公告）日：2014-10-09

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 2B . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文介绍了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物还可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠的重吸收。这些化合物还可以用于治疗对降低血压有反应或预计会有反应的疾病或病况。特别描述了这些化合物用于治疗心血管和肾脏疾病。